Table 6.

Overall survival in the published trials, compared to standard treatments

	Dose (viral particles)	6-Month survival (%)	12-Month survival (%)	Median survival (range) months	References
Published trials	All	40	9	NR (range 2–18 +)	Mulvihill et al. (2001)
	All	67	29	7.5 (NR—36 +)	Hecht et al. (2003)
	All	100	NR	NR	Lee et al. (2020)
	1011	0	0	3.5 (2.7–10.5)	Barton et al. (2021)
	3 × 1011	33	0	4.8 (1.6–5.4)
	1012	83	83	18.1 (3.5–20.0)
	All	25	12.5	NR (0.7–31 +)	Bazan-Peregrino et al. (2021)
	All (Part 2)	NR	NR	11.0 (5.0–48.4)	Garcia-Carbonero et al. (2022)
	All (Part 3)	NR	NR	13.5 (2.6–29.6 +)

	First-line agent	6-Month survival (%)	12-Month survival (%)	Median survival (95% CI) months	References
Standard therapies	FOLFIRINOX	75.9	48.4	11.1 (9.0–13.1)	Conroy et al. (2011)
	Gemcitabine + Nab-paclitaxel	67	35	8.5 (7.9–9.5)	Von Hoff et al. (2013)
	Gemcitabine	55	22	6.7 (6.0–7.2)	Von Hoff et al. (2013)